DMTK News and Press, DermTech Inc From 01/23/23

Molecular diagnostic company DermTech ( NASDAQ: DMTK ) added ~17% morning hours Monday after announcing favorable coverage policies from two commercial payers for its DermTech Melanoma Test (DMT). The decisions by Blues plan in Hawaii and an unnamed not-for-profit health plan in N...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from two commercial payers comprising a Blues plan in Hawaii and a physician-fou...

Summary The company's skin diagnostic test, dubbed DMT, has an uncanny ability to pick up the highly prevalent skin cancer, melanoma. Commercialization has been modest due to various launch barriers. Nevertheless, the company is exerting strong efforts to improve success. Recent Tri...

Have you ever been near the point of giving up on a stock but then found a reason for optimism? This story has repeated itself through the years -- sometimes with stocks that went on to become huge winners, such as Amazon and Apple . Investors already have a new example of this phenom...

Summary On January 3, 2023, an hour before the first opening bell of 2023, I published a list of my top 29 January Effect 2023 stocks. As of the close of business, January 11, 2023, this portfolio is up a blistering +21.4% whereas the Russell 2000 is up 4.7%. Although this is a very...

Molecular diagnostic company DermTech ( NASDAQ: DMTK ) is on track to record its higher-ever intraday gain on Tuesday after announcing that a foundational assay in its DermTech Melanoma Test has been recommended for TRICARE coverage. Defense Health Agency’s Lab Joint Working Gr...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the Defense Health Agency’s Lab Joint Working Group has recommended the Company’s foundat...

Summary IDEAYA caught a bid in the back end of FY22' as investors began to take notice of advancements in its clinical pipeline. The rally seems to have flattened into the new year, so we wanted to check if there's scope for it to extend further. The company's investigational compou...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina (...

Summary Clinical trial momentum within the Melanoma diagnostics and treatment paradigm is gaining steam. Immunocore Holdings plc presents with unique exposure for investors to position at the treatment end of the spectrum. Recent advancements in its investigational compounds are wel...